A major pharma announcement just made headlines: Eli Lilly’s next-generation peptide drug retatrutide demonstrated nearly 29 % average body weight reduction in late-stage clinical trials — one of the strongest results seen yet in obesity therapy. These impressive outcomes also included improvements in knee pain and metabolic health markers, signalling wide therapeutic value beyond simple weight loss. Financial Times➡️ This is a major development for peptide-based metabolic drugs, showing how targeted peptide therapeutics are now producing real clinical benefits with significant implications for millions of patients living with obesity and related conditions.

---